Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Indolent Non-Hodgkin Lymphoma × obinutuzumab × Lymphoid × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 80 Lymphoma, Follicular 46 Lymphoma, Non-Hodgkin 33 Lymphoma 27 Lymphoma, Large B-Cell, Diffuse 23 Lymphoma, Mantle-Cell 21 Lymphoma, B-Cell, Marginal Zone 20 Lymphoma, B-Cell 16 Recurrence 12 Neoplasms 9 Leukemia, B-Cell 5 Burkitt Lymphoma 5 Waldenstrom Macroglobulinemia 3 Neoplasm, Residual 3 Leukemia 3 Leukemia, Hairy Cell 2 Tumor Lysis Syndrome 1 Part1: Advanced B-cell Malignancies 1 Mycosis Fungoides 1 Mature B-cell Malignancies 1 Mature B-Cell Malignancies 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma, T-Cell, Cutaneous 1 Lymphatic Diseases 1 Leukemia, Prolymphocytic, B-Cell 1 Leukemia, Prolymphocytic 1 Leukemia, Myeloid, Acute 1 Leukemia, Lymphoid 1 Indolent Non-Hodgkin's Lymphoma 1 Indolent Non-Hodgkin Lymphoma 1

Interventions

obinutuzumab 1 ibrutinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02689869 2021-05-07

Alternative

Ludwig-Maximilians - University of Munich

Phase 2 Unknown

Indolent Non-Hodgkin Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡